3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
11
Lung Neoplasms
6
Colonic Neoplasms
5
Pancreatic Neoplasms
3
Pain, Postoperative
3
Inflammatory Bowel Diseases
3
Diverticulitis
3
Carcinoma, Hepatocellular
3
Urinary Bladder Neoplasms
2
Male Urogenital Diseases
2
Leiomyoma
2
Inflammation
2
Carcinoma, Non-Small-Cell Lung
2
Abdominal Cancer
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Skin Neoplasms
1
Shoulder Pain
1
Respiration Disorders
1
Psychological Well-Being
1
Postoperative Complications
1
Post-thoracotomy Pain Syndrome
1
Neoplasms
1
Mouth Neoplasms
1
Motor Activity
1
Lymphoma, Non-Hodgkin
1
Interventions
Cisplatin
160
Fluorouracil
134
Paclitaxel
125
Radiotherapy
117
Oxaliplatin
87
Carboplatin
71
Docetaxel
70
Irinotecan
59
pembrolizumab
57
Capecitabine
57
Leucovorin
56
Radiation
47
Surgical Procedures, Operative
33
Drug Therapy
33
Esophagectomy
31
Cetuximab
25
Neoadjuvant Therapy
24
Nivolumab
23
Bevacizumab
21
Trastuzumab
20
camrelizumab
19
S 1 (combination)
19
Chemoradiotherapy
17
Albumin-Bound Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Epirubicin
15
tislelizumab
14
Taxes
13
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Neoplasms
×
Tea
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled